WallStreetZenWallStreetZen

NASDAQ: ABP
Abpro Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ABP stock forecasts and price targets.

Forecast return on equity

Is ABP forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ABP forecast to generate an efficient return on assets?

Company
-1,643.16%
Industry
27.37%
ABP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABP earnings per share forecast

What is ABP's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$6.97
Avg 2 year Forecast
-$10.30

ABP revenue forecast

What is ABP's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

ABP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABP$1.95N/AN/A
IMRN$0.91N/AN/A
XBIO$2.33N/AN/A
CYCN$1.37N/AN/A
ACXP$2.50$31.00+1,142.48%Buy
View Top Biotech Stocks

Abpro Holdings Stock Forecast FAQ

What is ABP's earnings growth forecast for 2026-2027?

(NASDAQ: ABP) Abpro Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 201.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,212.07%.

Abpro Holdings's earnings in 2026 is -$22,040,000.On average, 2 Wall Street analysts forecast ABP's earnings for 2026 to be -$18,929,741, with the lowest ABP earnings forecast at -$18,367,472, and the highest ABP earnings forecast at -$19,679,434.

In 2027, ABP is forecast to generate -$27,983,096 in earnings, with the lowest earnings forecast at -$27,151,915 and the highest earnings forecast at -$29,091,337.

If you're new to stock investing, here's how to buy Abpro Holdings stock.

What is ABP's revenue growth forecast for 2026-2027?

(NASDAQ: ABP) Abpro Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,114.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,552.9%.

Abpro Holdings's revenue in 2026 is $0.On average, 2 Wall Street analysts forecast ABP's revenue for 2026 to be $0, with the lowest ABP revenue forecast at $0, and the highest ABP revenue forecast at $0.

In 2027, ABP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ABP's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: ABP) forecast ROA is -1,643.16%, which is lower than the forecast US Biotechnology industry average of 27.37%.

What is ABP's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ABP) Abpro Holdings's current Earnings Per Share (EPS) is -$14.19. On average, analysts forecast that ABP's EPS will be -$6.97 for 2026, with the lowest EPS forecast at -$6.76, and the highest EPS forecast at -$7.25. In 2027, ABP's EPS is forecast to hit -$10.30 (min: -$10.00, max: -$10.71).

What is ABP's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: ABP) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.